Philip Meese

In this engaging discussion, Philip Meese, a seasoned rheumatologist, delves into the latest advancements in IL-17 treatments for psoriatic arthritis and axial spondyloarthritis. He shares intriguing real-world data on the efficacy and safety of Bimekizumab, highlighting significant improvements in pain and fatigue. The conversation also explores treatment strategies comparing TNF and IL-17 inhibitors, revealing insights from a large patient study. Additionally, Meese discusses the long-term safety profile of Bimekizumab and other emerging therapies, emphasizing personalized patient care.

Catherine Bakewell, a seasoned rheumatologist and ultrasound expert, Philip Meese, a dedicated researcher on bimekizumab, and Artie Kavanaugh, an insightful rheumatologist reporting on ACR updates, dive into cutting-edge topics. They discuss the promising results of bimekizumab in alleviating pain and fatigue in psoriatic arthritis. Insights into the implications of weight loss drugs on treatment outcomes are explored, alongside crucial findings on sex differences affecting disease impact, driving home the need for tailored strategies in patient care.